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2. Summary  
Background: Acute leukemia (AL) is characterized by a complex spectrum of coagulopathy 
ranging from a high bleeding risk to thrombotic risk, varying according to disease phases and 
treatments. To date platelet count and conventional coagulation tests (CCTs) have been unable 
to predict thrombotic and hemorrhagic risk in AL.  
Objectives: Thromboelastography (TEG) is a global haemostatic test that measures the 
viscoelastic properties of the clot, thus providing information on the entire process of blood 
coagulation. The primary aim of this study was to assess with TEG the coagulation balance in 
patients with AL, from diagnosis to the end of first cycle of chemotherapy (CHT).  
Methods: Assessment of CCTs and TEG were made at the following time points: 1) Diagnosis 
of AL (T0); 2) during the first cycle of CHT (T1); 3) during myelosuppression T2 (PLT < 
30x109/L, absolute neutrophil count < 1000/mmc); 4) At the end of the first cycle of CHT (T3). 
Patients were followed-up for bleeding and thrombotic episodes daily up to the time of hospital 
discharge or death.   
Results: Forty consecutive patients were included. Comparing TEG results, we found that the 
most clinically significant changes emerged during CHT, including the myelosuppression 
phase, and after CHT. TEG identifies a hypocoagulable state on CHT, exacerbated during 
myelosuppression, and a hypercoagulable state after CHT. When CCTs and TEG results were 
compared based on the type of complications (thrombosis or hemorrhages), no differences were 
found at each analyzed time point.  
Conclusions: Cumulative, our findings showed the capacity of TEG revealing complex and 
dynamic abnormalities in patients with AL according to course of disease and treatment, respect 
coagulation test. Further studies will investigate the role of TEG in defining hemostatic profile 
and in individualizing the approach to transfusion and anticoagulant therapy/prophylaxis in 





Hemostatic balance alterations in either thrombotic or haemorrhagic sense are frequently 
reported in haematological neoplasms with a significant impact on morbidity and mortality.1,2 
Hematological patients treated with chemotherapy, experience clinically significant bleeding in 
up to 43% of cases and life-threatening bleeding in 1%. 3 Patients affected by acute leukemia 
experience specific abnormalities of the hemostatic system. Intensive chemotherapy is the 
backbone of  first line treatment of acute leukemia, it causes bone marrow failure and severe 
thrombocytopenia usually lasting for 2–3 weeks.4. Severe thrombocytopenia predisposes 
patients to an increased risk of fatal hemorrhages.  Despite the high bleeding risk,  the incidence 
of venous thromboembolism (VTE)  in acute leukemia is also not negligible ranging from about 
2% up to 12% according available studies 2. Approximately 5% of adult patients with acute 
leukemia may experience VTE within the first 2 months after diagnosis 5. The pathogenesis of 
VTE in the context of acute leukemia is multifactorial depending on: 1) pro-coagulant 
properties of leukemic cells; 2) patients related factors; 3) chemotherapy; 4) presence of central 
venous catheter (CVC) and of septic complications. 6 In summary acute leukemia is 
characterized by a complex spectrum of coagulopathy ranging from a high bleeding risk to 
thrombotic risk, varying according to disease phases and treatments.7 Conventional coagulation 
tests (CCTs) include prothrombin time (PT), international normalized ratio (INR), activated 
partial thromboplastin time (APTT), fibrinogen (FBG) concentration and D-dimer (DD) level. 
These tests are not able to assay interactions between clotting factors, blood cell elements and 
vascular endothelium. 8,9. Moreover, they have been validated to monitor vitamin K antagonists 
and heparin therapy , thus they cannot  predict and/or guide therapy in acute hemorrhages.10 
Current CCTs are  also unable to predict thrombotic in acute leukemia 11. Moreover, bleeding 
complications are quite uncommon in non-neoplastic thrombocytopenia, others factors must be 
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involved to explain an increased bleeding tendency in patients with acute leukemia under 
chemotherapy. Thromboelastography (TEG) is a global haemostatic test that measures the 
viscoelastic properties of the clot, thus providing information on the entire process of blood 
coagulation, from the early phase of clot formation to fibrinolysis. 12 During the last years, TEG 
has become a valuable tool in detecting coagulopathies and guiding hemostatic and transfusion 
therapies in different clinical settings including trauma care, cardiac surgery and liver 
transplantation 12-13. Moreover, it is adopted to monitor hemorrhage and guide therapy during 
obstetric surgery, within the emergency intensive care units (ICU) 14,15. The implementation of 
TEG offers several advantages considering that it is a fast and inexpensive assay, results can be 
available within five to ten minutes. Considering the advantages offered by TEG, its 
employment is growing-up in other contests and recently TEG has been adopted to predict 
thromboembolic events and hypercoagulability in patients with malignancies including 
hematologic malignancies.16-17 
Ideally, TEG instrumentation is commonly available in ICU and in cardiology surgery units, 
thus it can be easily accessible. However, to date there has been limited research investigating 
the use of TEG in patients with acute leukemia mainly focused on predicting bleeding risk in 
presence of thrombocytopenia. 18-26  
Since a clinical perspective, the employment of TEG to evaluate global hemostasis may provide 
a better in-vivo assessment of the haemostatic balance in patients affected by acute leukemia 
during the different phases of the disease. The primary aim of this study was to assess with TEG 





4.  Acute leukemia  
Acute leukemia (AL) is a proliferation of immature bone marrow-derived cells (blasts) that 
may also involve peripheral blood or solid organs. As a result, there is an accumulation of 
leukemic blasts or immature forms in the bone marrow, peripheral blood, and occasionally in 
other tissues, with a variable reduction in the production of normal red blood cells, platelets, 
and mature granulocytes. The percentage of bone marrow blast cells required for a diagnosis of 
acute leukemia is 20% for many leukemia types, and do not require any minimum blast cell 
percentage when certain morphologic and cytogenetic features are present. The diagnosis and 
classification of AL is based on morphology, immunophenotype, and cytogenetic/molecular 
features of blood, bone marrow, lymph node, or other tissue. The first attempt at classifying AL 
was the French American British (FAB) Cooperative Group morphological criteria that divided 
acute myeloid leukemia (AML) into 8 subtypes (M0 to M7) and acute lymphoblastic leukemia 
(ALL) into 3 subtypes (L1 to L3) according to degree of maturation. The FAB classification 
system can be useful, but it does not take into account many of the factors that are now known 
to affect prognosis. The World Health Organization (WHO) system, most recently updated in 
2016, includes some of these factors to try to better classify AL. 19   
The WHO 2016 classification distinguishes six groups of AML: (1) AML with recurrent 
genetic abnormalities, (2) AML with myelodysplasia-related changes, (3) Therapy-related 
myeloid neoplasms, (4) AML Not Otherwise Specified, (5) Myeloid sarcoma, and (6) Myeloid 
proliferations related to Down syndrome. As regard ALL, in 1997 WHO identified three types 
of ALL: B lymphoblastic, T lymphoblastic and Burkitt-cell Leukemia. Later revised in 2008, 
Burkitt-cell Leukemia was eliminated as it is no longer seen as a separate entity from Burkitt 
Lymphoma, and B-lymphoblastic leukemia was divided into two subtypes: B-ALL with 
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recurrent genetic abnormalities and B-ALL not otherwise specified. B-ALL with recurrent 
genetic abnormalities is further delineated based on the specific chromosomal rearrangement 
present. In 2016, WHO classification added two new provisional entities to the list of recurrent 
genetic abnormalities and the hypodiploid was redefined as either low hypodiploid or 
hypodiploid with TP53 mutations. In adults, B-cell ALL accounts for 75% of cases while T-
cell ALL comprises the remaining cases.  Immunophenotyping is required to distinguish T-cell 
ALL from B-cell ALL. 
4.1 Acute Myeloid Leukemia (AML) 
4.1.1 Epidemiology 
Acute myeloid leukemia (AML, also known as acute myelogenous leukemia) consists of 
a group of relatively well-defined hematopoietic neoplasms characterized by a clonal 
proliferation of myeloid precursors with a reduced capacity to differentiate into more mature 
cellular elements. AML is the most common acute leukemia in adults, accounting for ~ 80 
percent of cases in this group.  The incidence of AML increases with age, from ~ 1.3 per 100 
000 population in patients less than 65 years old, to 12.2 cases per 100 000 population in those 
over 65 years. Although advances in the treatment of AML have led to significant 
improvements in outcomes for younger patients, prognosis in the elderly who account for the 
majority of new cases remains poor. Even with current treatments, as much as 70% of patients 
65 years or older will die of their disease within 1 year of diagnosis. 20 AML has been associated 
with environmental factors (eg, exposure to chemicals, radiation, tobacco, chemotherapy) and 
genetic abnormalities (eg, trisomy 21; Fanconi anemia; Bloom's syndrome; familial mutations 
of CEBPA, DDX41, RUNX1). In some patients, evolution to AML is preceded by evidence of 
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clonal hematopoiesis manifest as myelodysplastic syndrome, myeloproliferative neoplasms, 
paroxysmal nocturnal hemoglobinuria, and aplastic anemia. 
 
4.1.2 Signs and symptoms 
The increased production of malignant cells, along with a reduction in these mature 
elements, results in a variety of systemic consequences including anemia, bleeding, and an 
increased risk of infection. The signs and symptoms reflect the development of anemia; 
however, weakness, loss of sense of well-being, and fatigue on exertion can be disproportionate 
to the severity of anemia. Easy bruising, petechiae, epistaxis, gingival bleeding, conjunctival 
hemorrhages, and prolonged bleeding from skin injuries reflect thrombocytopenia and are 
frequent early manifestations of the disease. Very infrequently, gastrointestinal, genitourinary, 
bronchopulmonary, or central nervous system (CNS) bleeding occurs at the onset of disease. 
Pustules or other minor pyogenic infections of the skin and of minor cuts or wounds are most 
common. With intensification of neutropenia and monocytopenia after chemotherapy, major 
bacterial, fungal, or viral infections become more frequent. Anorexia and weight loss are 
frequent findings. Fever is present in many patients at the time of diagnosis. Palpable 
splenomegaly or hepatomegaly occurs in approximately one-quarter of patients. 
Lymphadenopathy is extremely uncommon, except in the monocytic variant of AML. 2021 
 
4.1.3 Prognostic factors 
The diagnosis is made by the presence of ≥20% blasts in the peripheral blood or in the 
bone marrow, or through the presence of unique genetic abnormalities found in the bone 
marrow regardless of blast count [t(8;21), inv(16), or t(15;17)]. Accurate assessment of 
prognosis is central to the management of AML. By stratifying patients according to their risk 
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of treatment resistance or treatment-related mortality (TRM), prognostic factors help guide the 
physician in deciding between standard or increased treatment intensity, consolidation 
chemotherapy or allogenic hematopoietic stem cell transplant, or more fundamentally in 
choosing between established or investigational therapies. Among clinical factors, increased 
age and poor performance status are both associated with lower rates of complete remission 
(CR) and decreased overall survival (OS). Age and performance status at diagnosis similarly 
help to predict the risk of TRM, although multivariate model analyses suggest that other 
variables such as platelet count, serum creatinine or albumin rather than age itself account for 
most of the increased risk of TRM seen in older patients. Therapy-related AML and AML 
associated with a prior hematological malignancy also carry a significantly poorer prognosis. 
Although clinical factors have an important role in guiding therapy, cytogenetic changes 
constitute the single strongest prognostic factor for CR and OS in AML. AML is further 
classified into three prognostic risk groups: favorable, intermediate, and adverse. These are 
based on both cytogenetics and relatively recent recognition of molecular diseases subsets that 
are distinct from the contribution of cytogenetic risk. These newly recognized molecular subsets 
have different responses to standard therapeutics. The prognostic groups predict the response 
to standard therapy and survival in one large retrospective analysis of patients under the age of 
55, the overall survival rate at 5 years was 44%, however when broken down by risk profile the 
overall survival rates were 64%, 41%, and 11% for favorable, intermediate, and adverse risk 
respectively. The overall survival decreases when older adults are included but the stratification 









The general approach to current therapy has not changed substantially in recent years 
and usual treatment of AML includes an initial program termed the induction phase. The main 
treatment for most types of AML is chemotherapy, sometimes along with a targeted therapy 
drug. This might be followed by a stem cell transplant. Other drugs (besides standard 
chemotherapy drugs) may be used to treat people with acute promyelocytic leukemia (APL). 
Choice of initial induction treatment depends on functional status of the patient, biological 
status of the disease (best measured by prognostic risk groups and recently recognized 
molecular profile of leukemia cells) and goals of the patient. Initial assessment evaluates 
whether a patient is considered a candidate for intensive induction chemotherapy.  
The two commonly used induction therapies in acute myeloid leukemia include 1) Cytotoxic 
chemotherapy with or without targeted therapies and 2) Hypomethylating agents with or 
without targeted therapies. 24  
 A combination of anthracycline and cytarabine has been the standard induction therapy since 
1973. A now classic standard induction regimen is cytarabine 100 mg/m2 daily by continuous 
infusion on days 1 through 7 and daunorubicin at 45 to 90 mg/m2 on days 1 through 3 
(commonly referred to as “7+3” regimens).25 This induction therapy, leads to complete disease 
response in up to 80% of patients with favorable risk disease and 50–60% complete response 
in those with intermediate adverse risk disease. 
The outcomes have improved with addition of various targeted drugs to the traditional 7+3 
induction chemotherapy in the favorable and intermediate risk groups. Gemtuzumab 
ozogomycin (GO) is a monoclonal antibody against CD-33 (a protein that is expressed in 
myeloid leukemia cells). Addition of GO to standard chemotherapy in patients with favorable 
and intermediate risk disease decreases the risk of relapse and in some studies improves OS. 26 
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Midostaurin is an oral multi-targeted tyrosine kinase inhibitor (TKI) active in patients with a 
FLT3 mutation. FLT3 mutations initiate oncogenic signal transduction in about 25–30% of 
patients with AML. Addition of midostaurin to standard 7+3 chemotherapy in patients with 
FLT3 mutation has improved survival, from a median of 25 to 74 months. 27 Intensive induction 
therapy has many complications, but myelosuppresion, which manifests as neutropenia, 
thrombocytopenia and anemia, is one of the most important and mainly responsible for the 
mortality of AML patients. 28 Once a remission is obtained, further treatment is indicated to 
preserve the remission state.  
 
4.2 Acute lymphoblastic leukemia (ALL) 
  4.2.1 Epidemiology 
Acute lymphoblastic leukemia (ALL) is a malignant transformation and proliferation of 
lymphoid progenitor cells in the bone marrow, blood and extramedullary sites. The estimated 
annual incidence of ALL-worldwide is 1 to 5 cases/100,000 population, and more than two-
thirds of cases of ALL are B cell phenotype. While 80% of ALL occurs in children, it represents 
a devastating disease when it occurs in adults. Within the United States, the incidence of ALL 
is estimated at 1.6 per 100 000 population. In 2016 alone, an estimated 6590 new cases were 
diagnosed, with over 1400 deaths due to ALL (American Cancer Society). The incidence of 
ALL follows a bimodal distribution, with the first peak occurring in childhood and a second 






4.2.2 Prognostic factors 
Prognosis in B-ALL/LBL is associated with age, white blood cell count, race, male sex, 
and cytogenetic/genetic features.  Increasing age and elevated white blood cell count at 
diagnosis, defined as 30 × 109 for B-ALL or 100x109 for T-ALL, portend a worsening 
prognosis.  The cytogenetic aberration with the greatest impact on prognosis and treatment is 
the presence of the Philadelphia chromosome, t(9;22). The prevalence of t(9;22) in adult ALL 
can range from 15–50% and increases with age. Ph positivity has implications both in terms of 
prognosis and for treatment. In addition to disease characteristics at the outset, it has long been 
recognized that response to initial therapy predicts outcome. 
 
4.2.3 Signs and symptoms 
Most of the clinical manifestations of ALL reflect the accumulation of malignant, poorly 
differentiated lymphoid cells within the bone marrow, peripheral blood, and, extramedullary 
sites. Presentation can be nonspecific, with a combination of constitutional symptoms and signs 
of bone marrow failure (anemia, thrombocytopenia, leukopenia). Common symptoms include 
‘B symptoms’ (fever, weight loss, night sweats), easy bleeding or bruising, fatigue, dyspnea 
and infection. Involvement of extramedullary sites commonly occurs and can cause 
lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients. CNS involvement at time 
of diagnosis occurs in 5–8% of patients and present most commonly as cranial nerve deficits or 







The structure of treatment of adult ALL has been adapted from pediatric protocols. 
Unfortunately, while long-term survival approaches 90% for standard-risk pediatric ALL, the 
success rate is much more modest in adults. Chemotherapy consists of induction, consolidation 
and long-term maintenance, with CNS prophylaxis given at intervals throughout therapy. The 
goal of induction therapy is to achieve complete remission and to restore normal hematopoiesis. 
The backbone of induction therapy typically includes vincristine, corticosteroids and an 
anthracycline.  The role of L-asparaginase, while standard in pediatric protocols, is a challenge 
in adults at times due to the increased rate of adverse events. 30  L-asparaginase decreases 
plasminogen, fibrinogen, and antithrombin, resulting in impaired thrombin inhibition, which 
may contribute to the asparaginase related dose-limiting toxicity. Changes in antithrombin (AT) 
and fibrinogen during induction chemotherapy with L-asparaginase were reported in a 
retrospective study of 214 adult patients with ALL. While dose intensification strategies have 
led to a significant improvement in outcomes for pediatric patients, prognosis for the elderly 
remains very poor.29 Despite a high rate of response to induction chemotherapy, only 30–40% 
of adult patients with ALL will achieve long-term remission. 29  
Special consideration must be made in the treatment of Ph-positive ALL. Historically, Ph-
positive ALL was a very bad player with 5-year survival 5–20% and Allo-SCT being the only 








4.3 Bleeding and thrombosis in acute leukemia  
The course of acute leukemia may be accompanied by various abnormalities of hemostasis, 
from severe thrombocytopenia to subclinical activation of clotting or chronic disseminated 
intravascular coagulation (DIC). Clinical manifestations can range from localized venous 
and/or arterial thrombosis to diffuse life-threatening bleeding. The incidence of these 
complications varies according to the type of leukemia and the phase of treatment.  
In adult patients with AL the 6%–7% of whom experience serious to life-threatening bleeding: 
ie, WHO grades 3 and 4; resulting in mortality or lasting morbidity, or requiring medical 
intervention. Intracranial hemorrhage (ICH) is the second most common complication, after 
infective complications.  32 
Even if severe thrombocytopenia is considered a key factor, the definite cause of ICH in patients 
with hematological malignancies is inconclusive. Chemotherapy related endothelial injury and 
reduction of coagulation factors also could play a role in the pathogenesis of ICH.1,6  
To prevent serious and spontaneous bleeding, prophylactic platelet transfusion is standard of 
care for patients affected by AL when showed a low platelet counts. 
Currently, these platelet transfusions are given prophylactically when the platelet count is below 
10×109/L. Even if the platelet count is the main trigger for prophylactic platelet transfusions, it 
per se is poorly correlated with bleeding risk, since a significant percentage of bleeding episodes 
might occur at relatively high platelet counts and despite platelet transfusions.33  
On the other hand, although venous thromboembolism (VTE) has been considered less 
characteristic than hemorrhage in patients with AL, recent studies suggest that thrombosis is 
more common than previously appreciated 34.   
The reasons for this increase in thrombotic risk are complex and poorly understood. The 
pathogenesis of VTE in the context of AL is multifactorial depending on: 1) pro-coagulant 
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properties of leukemic cells; 2) patients characteristics; 3) therapeutic interventions; 4) presence 
of central venous catheter (CVC) and of septic complications. 6,16 
Among the postulated mechanisms for chemotherapy-related thrombosis are: (1) release of 
procoagulant products from apoptotic malignant cells; (2) drug toxicity directed at the vascular 
endothelium; (3) direct induction of monocyte or tumor-cell Tissue-Factor (TF); and, (4) a 
decrease in physiological anticoagulants. 1 
VTE incidence in AL ranges from about 2% up to 12%5, 35-36. Ku et al. 5 have observed a 2- 
year VTE cumulative incidence of 5.2% in AML and 4.5% in ALL, in a cohort study on 7876 
patients with acute leukemia, mainly during the first month of diagnosis: age, comorbidities 
and CVC were reported as the most frequent associated risk factors for VTE. 
De Stefano et al. 35 evaluated the risk of VTE in a cohort of 379 adult patients with a newly 
diagnosed AL; overall, VTE episodes occurred in 19 (5%) patients and in 13 cases of entire 
population (3.4%), it was the presenting manifestation. In particular, VTE at diagnosis was 
observed in 1.4% of ALL, 9.6% of APL and 3.2% of other AML. Moreover, patients treated 
with L-asparaginase had a 4.9 fold increased risk of thrombosis (95%CI: 1.5–16). 
Death rate due to thrombosis was 0.8% and, differently from AML, in ALL the occurrence of 
VTE increase of 40% the risk of dying within 1 year. Estimated incidence of VTE in children 
with ALL, derived from prospective studies, range from 3% to 36.7%2 . A meta-analysis of 17 
studies showed a 5.2%, rate of thrombosis in pediatric patients with ALL mainly during 
induction therapy with L-asparaginase36. A similar trend (incidence rate of 5.9%) was observed 
in adults with ALL from 13 published prospective studies including 323 patients 37. Most VTEs 
occurred within 3 months from diagnosis; however, most of them were upper extremity CVC 
related deep vein thrombosis and occurred mainly in ALL.  
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Since patients with acute leukemia have a high risk of hemorrhage, the administration of 

























5.  Conventional coagulation tests 
A model of the plasmatic coagulation distinguishes an extrinsic pathway, which starts with 
tissue factor/factor VII activation, an intrinsic pathway that is activated by contact factors, and 
a common pathway comprising the coagulation factors II, V and X. The coagulation cascade is 
a tightly controlled series of enzymatic and cell-based reactions, designed to generate thrombin, 
which converts fibrinogen to fibrin, and requires co-factors such as phospholipids and calcium 
ions. It is usually subdivided into an initiation phase, an amplification phase and a propagation 
phase. 40 
Conventional coagulation tests (CCTs) assess blood coagulation and include prothrombin time 
(PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), 
platelet count, fibrinogen concentration, D-dimer level. PT, described first by Quick in 1935, is 
still referred as “Quick’s PT” or “Quick value”. Originally developed to determine PT (factor 
II of the coagulation cascade), it is now clear that it depends especially on factor VII together 
with the factors X, V, II and fibrinogen. 41 Changes over time have made the test more specific 
for the vitamin K dependent clotting factors (VII, X, V and II). The initiation of clotting, 
specifically of the intrinsic pathway, is naturally triggered by negatively charged phospholipid 
surfaces (platelet). This reaction is artificially replaced by contact phase activators. In the past 
through cephalin, currently through minerals as kaolin or celite and more rarely silica or glass 
dust. The APTT depends initially on factor XII and XI and reflects the intrinsic pathway, 
especially factors VIII, IX and XI. Originally designed in 1953 as a simple one-stage test for 
hemophilia. At that time, the test was activated by cephalin (phospholipid) and consequently 





These tests are usually used for the clinical diagnosis of coagulopathy, to monitor 
anticoagulation therapy, and to assist in the treatment of bleeding episodes.11 Despite being 
very effective for specific clinical needs, such as anticoagulation monitoring, they have 
limitations. Their main disadvantage in circumstances of acute major bleeding is long 
turnaround time. 
These tests are plasma-based assays evaluating the thrombin generation determined by pro-
coagulation factors but ignore the interaction of the coagulation factors with blood cell elements 
and the vascular endothelium.43 Furthermore, they are enable to assess PLT function, the 
activity of the fibrinolytic system and endogenous anticoagulant factors. They reflect the 
situation in vivo only partially, and may be influenced by a variety of pre-analytical factors.  
Similarly, fibrinogen according to Clauss may overestimate the fibrinogen concentration in the 
presence of hydroxyethyl starch.  
Platelet concentration, easily measured as part of a complete blood count, does not 
necessarily reflect their function, especially in the presence of elements known to affect platelet 
reactivity, antiplatelet agents, uremia, malignancy, or alcohol intake. VTE is another common 
and serious condition that is associated with abnormal blood coagulation. In these cases, 
systemic hypercoagulability shifts the body’s homeostatic mechanisms toward a pro-
thrombotic state. Common coagulation testing has not been shown to predict such events, and 








6.  Thromboelastography (TEG) 
Thromboelastography (TEG) is a point of care (POC) viscoelastic test of hemostasis which 
allows measurement of haemostatic function, from the beginning of clot formation to the end 
of fibrinolysis, including initiation, formation, and stabilization of the clot.  
TEG was developed and first described by Hartert at the University of Heidelberg (Germany) 
in 1948 and its use in clinical practice was not described until many years later (1960s) when 
physicians performing early liver transplantation surgeries described use of TEG to detect and 
treat fibrinolysis occurring after reperfusion of the transplanted liver. Successively in 1990s, 
TEG was demonstrated to be useful in cardiac surgery. 44,45 TEG is a laboratory method that 
demonstrates the interactions among the blood cells and their biochemical characteristics by 
means of a graphic representation. The principle of this in vitro test is to detect and quantify 
dynamic changes of the viscoelastic properties of a blood sample during clotting under low 
shear stress.  The test is performed in a specially designed system called a thromboelastograph 
(Figure 1). The system consists of two chambers simultaneously examining a blood sample in 
duplicate to reduce the risk of sampling and measurement errors. Each chamber consists of a 
plastic plate, upon which is placed a disposable cup, attached via mechanical arms to the TEG 
device. Whole blood is placed in the disposable cup, and after activation of clotting (usually 
with kaolin), the plastic plate and cup are moved up into contact with the pin. Induced pin 
movement is recorded and changes measured as a function of time. At this point, the TEG 
tracing is initiated. After the tracing is initiated, the mechanical arms on the TEG instrument 
rotate the cup at a fixed frequency. Initially the pin, attached to the instrument via a torsion 
wire, will be motionless in the cup of whole blood as there is no means for the liquid whole 
blood to exert force on the pin. As whole blood coagulates, the viscosity of the blood increases 
and at the same time the pin becomes cross-linked to the cup via fibrin and platelet interactions. 
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These gradually increasing viscoelastic mechanical properties of the blood are reflective of the 
developing 3-dimensional fibrin mesh and platelet components of the clot. The greater the 
viscoelasticity of the clot, the higher the amplitude of the pin motion. The thromboelastogram 
(Figure 2) is a graphical image of the recorded amplitude of movement of the pin as a function 
of time. Analytical software measures and quantifies these changes. Whole blood for TEG 
analysis is usually collected in sodium citrated VacutainerVR® tubes and then recitrated when 
the whole blood sample is pipetted into the sample cup. Non-citrated whole blood (native blood 
TEG) can also be tested, but it must be used immediately. The test and reagents used are at 
room temperature. A volume of 340 uL of citrated blood is pipetted to the study cup, recalcified 
by the addition of 20 uL of 0.2M calcium chloride and then activated with a kaolin-cephalin 
reagent. Cephalins, or phosphatidylethanolamines, are a class of phospholipids commonly 
present in membranes of human cells. They are an important cofactor of the coagulation cascade 
which enables the assembly of tenase and prothrombinase complexes on the surface of platelets 
which are critical for thrombin generation. Kaolin is a mineral, primarily composed of hydrated 
aluminum silicate, which is a negatively charged molecule that can initiate the intrinsic 
coagulation pathway by activating Factor XII. Precise proportioning of the blood and kaolin-
cephalin reagent is important for accurate and reproducible TEG results. The parameters of the 
thromboelastogram include the reaction (R) time, the time from initiation of the TEG tracing 
until torsion is exerted on the pin/wire assembly. R time largely reflects the adequacy of 
coagulation factors (similar to what is measured in the laboratory by PT and aPTT). The K 
(time to reach 20 mm clot amplitude) and the angle (angle formed by line tangent to clot curve, 
Fig. 2) reflect clot kinetics and are determined by a number of factors including thrombin 
generation and fibrinogen concentration. The maximum amplitude (MA) is the maximum 
distance traveled by the cross-linked cup/pin, which reflects maximum clot strength and is 
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largely a function of platelet function or activity. Finally, the Lysis30 or Lysis60 is the percent 
decrease in area under the TEG curve (from MA) over 30 or 60 min. All of these parameters 
can be compared to normal or reference values to detect either clotting factor deficiencies 
(increased R time), fibrinogen deficiencies (decreased angle), platelet function defects 
(decreased MA), or excess fibrinolysis (Lys30 or Lys60 outside of reference values). The TEG 
tracing thus provides an overview of multiple coagulation processes and allows detection of 
variables that affect conventional coagulation tests, as well as factors that cannot be easily 
measured by conventional testing as clot kinetics, which is dependent upon both thrombin 
generation and fibrinogen concentration and platelet function. Another advantage of TEG over 
conventional coagulation testing is that the TEG R time is significantly more sensitive to 
clotting factor deficiencies or the presence of heparin than are conventional tests such as APTT 
or PT. A special cup containing heparinase can be used to determine whether the presence of 
heparin (administered therapeutically or through accidental sample contamination) has 
influenced the TEG parameters.46  
TEG analysis of patients with a history of thromboembolic complications showed shorter R 
values and accelerated clot propagation compared to healthy reference subjects.15 The TEG 
may be helpful in screening for hypercoagulable states. During the last years, these tests have 
been shown to be suitable for detecting and treating coagulopathy in trauma care, cardiac 
surgery and liver transplantation. As a point of care device, it may also monitor hemorrhage 
and control therapy during obstetric surgery, at the emergency department, and at the intensive 
care unit. 47 
Furthermore, TEG is recommended by guidelines to help detect, manage and monitor 
hemostasis in cardiac surgery patients. Another potential application of TEG is to improve 
diagnosis, prevention, and treatment of patients with VTE.                          
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The most appropriate evidence-based practice to prevent VTE is to stratify patients based on 
the VTE risk using one of the risk prediction models elaborated for surgical and medical 
patients. None of these models includes conventional blood coagulation tests since they do not 
predict VTE. A number of initial reports suggest that TEG may be a useful tool to help with 
risk stratification.48,16 To date, there have been reported cases of the utilization of TEG to 


















7. Materials and Methods  
7.1 Population 
A prospective observational pilot study was performed with the primary aim of assessing with 
TEG the haemostatic balance in patients with AL, from diagnosis to the end of chemotherapy. 
The secondary aim was a specifically analyze of TEG profiles in patients with clinically 
relevant thrombotic and/or haemorrhagic complications. The Ethics Committee of University 
Hospital of Palermo (number of protocol 04/2018) approved this study. Informed consent was 
collected from all participants according to the Helsinki declaration. Patients affected by AL, 
reporting at the Unit of Hematology of University Hospital of Palermo, fulfilling the inclusion 
criteria and providing informed consent, were consecutively enrolled from the beginning of 
May 2018 to the end of December 2019. Eligible patients were ≥18 years of age, with a new 
confirmed diagnosis of AL {acute myeloid leukemia (AML) and acute lymphoid (ALL)}. 
Diagnosis of AL was based on conventional morphocytochemical criteria, 
immunophenotyping, and cytogenetic and/or molecular tests according to WHO 
classification.19 The exclusion criteria were as follows: diagnosis of Acute Promyelocytic 
Leukemia (APL), known coagulation disorders, known liver diseases, concomitant solid 
neoplasms and regular use of anticoagulants. All the enrolled subjects received treatment 
regimens in accordance with international guidelines from the European LeukemiaNet (ELN) 
for disease type, age and comorbidities 22. According to standard practice, when the morning 
platelet count was <10x109/mL, patients received prophylactic transfusion with one batch of 
platelet concentrate; while target of Hb for transfusion was usually 8.0 g/dl and 8.5 g/dl in 
selected cases (active infection like acute pneumonia and known cardiovascular comorbidities). 
Number of platelet (PLT) and red blood cell (RBC) transfusion units received during the study 
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was recorded. Assessment of blood count cells (CBC), conventional coagulation tests (CCTs) 
including PT, a-PTT, DD, FBG and TEG were made at the following time points: 1) Diagnosis 
of AL (T0); 2) During the first cycle of CHT (T1); 3) During myelosuppression T2 (PLT < 
30x109/L, absolute neutrophil count < 1000/mmc); 4) At the end of the first cycle of CHT (T3). 
Baseline characteristics (age, comorbidities, type of leukemia, treatment received) were 
recorded in a dedicated database accessible to study staff and protected by password. 
Coagulation samples were collected at least 24 hours (h) after PLT or RBC transfusion, in 
absence of any concomitant anticoagulant treatment.  Patients were followed-up for bleeding 
and thrombotic episodes daily up to the time of hospital discharge or death.  Bleeding was 
graded 1 to 4 according to the WHO criteria. Thrombosis included VTE, superficial venous 
(SVT), arterial thrombosis, all objectively  diagnosed and confirmed using standard diagnostic 
testing (i.e. ultrasound and computed tomography). 
7.2 Thromboelastography (TEG) 
The TEG was performed on citrated whole blood samples within 2 hours after blood 
collection by a Haemoscope Thrombolastograph® Haemostasis Analyzer model 5000. Testing 
carried out by the same-trained biomedical scientists using citrated blood samples (340 ml) that 
were recalcified with 20 ml of 0.2 M CaCl2. The TEG parameters reaction time (R, min),  
(alpha-angle, ), kinetic time (K, min), maximum amplitude (MA, mm) and coagulation index 
(CI), were recorded. The normal reference ranges, defined by internal control, were considered 
as R 9-27 min, K 2-9 min,  22°-58°, MA 44-64 mm, CI -3;+3. Thrombin generation (TG) was 
indirectly calculated by an algorithm of the instrument and normal range was considered 494-




7.3 Blood count and coagulation tests 
Samples underwent hematology test and assayed using COBAS INTEGRA 800 
biochemical analyzer (Roche, Basel, Switzerland). APTTs and PTs were performed using on 
the automated coagulometer ACL TOP 750 series (Instrumentation Laboratory, Werfen)  and 
FBG was assayed using the Clauss method.                                                                                                                                  
The reagents and methodology were used according to the manufacturer’s instructions.                                                                                                                                                                                                     
Platelet‐poor plasma (PPP) was obtained by centrifugation of citrated blood at 10000 g for 5 
min and then at 1500 g for 3 min. All samples were collected at the appropriate time point and 
CBC, fibrinogen measurements were performed within 2 hours after blood collection. All other 
tests were performed batchwise in stored PPP (−80°C), which was frozen in aliquots within 2 
hours after blood collection. Normal reference ranges were taken from the reagents instructions: 
PT-ratio 0.8-1.2, APTT 24-36 sec, fibrinogen 150-450 mg/dl, DD 10-250 μg/L.   
  
7.4 Statistics  
Continuous variables are presented as mean ± standard deviation (SD) for normally 
distributed traits while categorical variables are expressed as counts and percentages. To 
evaluate the behavior of TEG parameters before, during and after chemotherapy the paired t 
test was used. It has been analyzed the difference between diagnosis and chemotherapy (T1 vs 
T0), during and after chemotherapy (T1 vs T3). Moreover, in patients who experienced 
myelosuppression we analyzed difference between this phase and chemotherapy (T2 vs T3) 
with the paired t test. We used Pearson's correlation to evaluate the relationship between TEG 
parameters and CCTs and between TEG parameters and the values of CBC.  Two-sided P values 
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of <.05 were considered statistically significant. Statistical analysis and graphs were performed 
using software Open Source R. 
 
8. Results  
8.1 Patients 
Forty consecutive patients were enrolled: 31 with newly diagnosed AML and 9 with ALL. 
As for disease molecular characteristics, we distinguished AML-NOS in 27 patients, FLT3-
mutation was found in 3 patients, AML with mutated NPM1 and AML with myelodysplasia-
related changes in two and one patient, respectively. AML was secondary to Polycythemia Vera 
(PV) in one patient; one patient had a Philadelphia Chromosome positive acute lymphoblastic 
leukemia (Ph+ALL).  Population consisted of 23 males (57%) and 17 females (43%) with a 
mean age of 62 years (range 18-80) and mean time of follow-up lasting 31 days (range of 7-
69).  Table 1 shows clinical and demographic characteristics of the enrolled patients.  
TEG at T0 was performed in all the enrolled patients (N=40), at T1 TEG was available for 
29 patients at T2 for 25 subjects. TEG at T1 was not carried out in 11 patients for the following 
reasons: 5 patients moved to another haematological center, 3 patients were not treated with 
CHT, receiving exclusively supportive therapy at home, 3 patients died after diagnosis, before 
the begging of CHT, for infective complications. T2 was not performed in four patients because 
three of them died during CHT and one received a continuative therapy with hydroxyurea. TEG 
during phase after CHT (T3) was carried out in fourteen patients with AML receiving high dose 
of CHT. Treatments administered were inductive chemotherapy (n=18), hypomethylating 
agents (HP) (n=9), tyrosine kinase inhibitor (TKI) (n=1) and hydroxyurea (n=1). Induction 
regimens adopted were cytarabine plus daunorubicine (7 plus 3) and fludarabine, cytarabine 
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and filgrastim (FLAG) for AML and vincristine, prednisone, cyclophosphamide, doxorubicin 
and L-Asparaginase for ALL. All cases with FLT3-mutated AML received also midostaurin. 
Primary antithrombotic prophylaxis was not administered in any enrolled patient. 
8.2 Hemostasis in acute leukemia patients at diagnosis 
TEG results at each time-point are summarized in Table 2, Figure 3. TEG parameters at 
baseline, showing the highest proportion of values outside interval reference range were R and 
MA, they resulted reduced in 47% and 35% of patients, respectively TG and K were also 
reduced (25% and 27% of results below reference intervals) while alpha-angle exceeded the 
normal range level in 14%. The mean PLT count was 66x109/L (SD+67x109/L) and it was 
positively related to MA by Pearson coefficients: 0.69 (p < 0.05). In addition, a strong 
correlation was observed between MA and alpha-angle, (Pearson’s coefficient 0.75, p < 0.05). 
As regard CCTs, mean values of APTT, PT/INR were within the normal reference range, while 
FBG was above the normal range in 11 patients and D-dimer levels were substantially increased 
in almost all patients. There was no significant correlation between CCTs and TEG parameters 
at the time of diagnosis. Table 3 summarizes parameters of CBC and CCTs.  
8.3 Haemostasis in acute leukaemia patients during chemotherapy  
At T1,  TEG parameters, analyzed in 29 patients, shifted toward a hypocoagulability 
state when compared to T0: MA (49 mm vs 41 mm; p< 0.05),    (50° vs 44°, p <0.05)  and TG 
(604 mm/min vs 531 mm/min, p<0.05) were decreased while K and CI were increased (K, 3.2 
vs 4.7 seconds, p<0.05; CI -0.15 mm to -0.22 mm, p>0.05). Otherwise R was shorter than T0 
(9.3 vs 8.6, p>0.05).  As regard CCTs, we found no significant differences compared to T0 and 
no correlation with global hemostasis test. Only the value of DD level appeared reduced during 
CHT (p>0.05). The value of PLT count was moderately reduced in comparison toT0 (55 + 51 
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x109/L) and it was still positively correlated with MA (Pearson’s coefficient 0.76, p<0.05). 
Finally, CBC parameters (Hb, Hct, Wbc) were significantly lower than at T0 (p<0.05). 
 
8.4 Haemostasis in acute leukaemia during myelosuppression  
TEG was performed in fourteen patients during the myelosuppresion phase (T2) after 
myeloablative treatment and compared to the other time-points (Table 2). In this phase, all TEG 
parameters were significantly shifted to hypocoagulable state in comparison to T1, in details: 
R and K were increased (R, 12 seconds vs 8.6 seconds, p<0.05; K, 7.8 vs 4.7 seconds, p<0.05) 
while alpha-angle and MA were decreased (, 29° vs 44°, p <0.05; MA, 25 mm vs 41 mm; p 
<0.05). TG and CI were reduced (TG, 467 mm/min vs 531 mm/min, p<0.05; CI -1.95 mm to -
0.22 mm, p<0.05). As expected, a significant reduction in all CBC parameters was detected 
with a severe thrombocytopenia.  Platelet count was significantly decreased (p < 0.01), from 55 
x109 /L + 51 (T1) to 4.7 x109 /L + 4.0 x 109/L (mean + SD). Furthermore, CCTs did not show 
a significant correlation with TEG during myelosuppression. Only DD levels resulted reduced 
at T2 (DD, 1469 vs 2125 μg/L).   
8.5 Haemostasis in acute leukemia patients after chemotherapy 
At T3, alpha-angle and MA were significantly wider than at T0 ( 61° vs 50°; MA 59 
mm vs 50 mm; p<0.05) and TG increased (735 mm/min vs 604 mm/min, p<0.05). K was 
slightly shorter (p> 0.05) and CI moderately increased.  TEG parameters at T3  appeared  
significantly modified also in comparison to T1(p<0.05) : , 61° vs 44°; MA, 59 mm vs 44 
mm; K 2.5 seconds vs 4.7 seconds, TG, 735 mm/min vs 531 mm/min; CI 0.69 mm to -0.22 
mm).  R-time was not significantly reduced compared to T0 and T1 (Figure 1). We found no 
significant changes in terms of CCTs and of their relationship with TEG parameters.  
30 
 
Platelets count was markedly increased compared to all the other time-points (T0, T1 
and T2).  At this time point persisted relationship between PLT and MA (p<0.05) as previous 
seen in the others. The values of Hb and Wbc, including absolute neutrophil count (ANC), were 
significantly increased (p<0.05) when compared to all the other time-points. Additionally, ANC 
showed a significant negative effect on K (Pearson’s coefficient -0.75, p<0.05) and on R 
(Pearson’s coefficient -0.65, p<0.05), and no impact on MA, angle and CI. TG appeared 
positively influenced by ANC (Pearson’s coefficient -0.82, p<0.05).  
 
8.6 Bleeding and thrombotic complications within the course of AL 
Among 40 patients sixteen (40%) had hemorrhagic symptoms: 4 had WHO grade 4 
bleedings, including central nervous system (CNS) hemorrhage (n=2),  bleeding secondary to 
ruptured spleen (n=1) and 1 sub retinal hemorrhage; 2 had WHO grade 3, including epistaxis; 
9 had WHO grade 2, including hematuria (n=2),   skin petechiae (n=4),  ecchymosis (n=1) and 
gum bleeding (n=1). Except one CNS-hemorrhage occurring in a patient with ALL, all bleeding 
complications were reported in patients with AML. In three patients, symptoms were reported 
during CHT (T1) (1 on hydroxyurea and 2 on HP), in four patients at AL diagnosis (T0) and in 
nine during mylosuppresion (T2). Overall, five patients (12%) experienced thrombotic 
symptoms: 2 deep vein thrombosis (DVT), 1 CVC related thrombosis, 1 portal vein thrombosis 
(PVT) and 1 pulmonary embolism (EP). In detail, three events occurred in AML patients: PVT 
was diagnosed before CHT (T0) in a patient with AML post-PV, while the other two 
complications occurred during CHT (T1).  Two thrombotic events occurred in two patients with 
ALL, 1 EP during induction therapy (T1) and the other (DVT) in post-CHT phase (T3).  There 
were no significant differences in terms of CCTs and TEG results between patients 
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experiencing hemostatic complications (bleeding and thrombosis) and those without, at either 
T0, T1, T2 or T3. Similarly, when CCTs and TEG results were compared based on the type of 
complications (thrombosis or hemorrhages), no changes were found at each analyzed time 
point. However, all the enrolled patients experiencing significant bleeding showed a trend 
toward a hypocoaguable state on TEG at T0, with longer R-times (mean 10.5 vs 8.25, p> 0.05) 
and K-times (4.15 vs 3.21, p> 0.05), in comparison to non-bleeders. Interestingly, in the patient 
with AML and CNS hemorrhage, some parameters of TEG (MA 24 mm, CI -4.7, TG 341 
mm/min) performed  at T2, the day before symptoms onset, resulted decreased. With reference 
to thrombotic complications, in 4 (80%) patients with VTE, TEG at T0 showed K and R below 
the reference values.  Overall, transfusion requirements, numbers of RBC (mean + SD, 9.7 + 
4.7 vs 5.1 + 3.1, p<0.05) and PLT units (mean + SD, 5.2+ 3.2 vs 0.55 + 2.8, p<0.05) transfused 
were significantly increased in symptomatic patients with bleeding and in those with 
thrombosis.  
9. Discussion  
TEG is a rapid and easy to handle tool, in contrast with other global tests requiring 
specialized centers, it is widely available in several hospitals. Our results showed that TEG is 
able to identify changes in the haemostatic state of patients with AL according to the course of 
the disease. At diagnosis, a large dispersion of TEG parameters was observed in newly 
diagnosed patients, with a wide variability from a hypocoagulable to a hypercoagulable state. 
Interestingly, in about half (47%) of leukemic patients, the most frequent sign of 
hypercoagulability was a shorter R-time, suggesting an underlying increase in coagulation 
factors plasma levels and activity. Indeed R-time can be considered, as PT/INR and a-PTT, a 
surrogate marker of clotting factor levels. 41 However, in the current study, PT/INR and a-PTT 
did not result abnormal at diagnosis. Unfortunately, we have not assayed coagulation factors, 
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however some authors have previously reported an increase in coagulation factor plasma levels 
in patients with AL before treatment. 49 According to these findings, TEG at diagnosis confirms 
the coagulation activation frequently observed in neoplastic patients and underlines the 
heterogeneity and complexity of haemostatic alterations in patients with AL 34, thus requiring 
an individual determination of the thrombotic and/or haemorrhagic risks.   
Comparing TEG parameters at all 4 time-points planned, we found that the most clinically 
and statistically significant changes emerged during and after cytoreductive  therapy, including 
myelosuppression phase. TEG identifies a hypocoagulable state during chemotherapy, further 
exacerbated on myelosuppression phase. In details, our results detected a slower rate of clot 
formation time (K-time and alpha-angle) during CHT, when compared to the time of diagnosis. 
Kim et al. showed that significant determinants of the K value were FVII, PLT and fibrinogen. 
50 However in this phase, platelets count resulted only moderately decreased respect to the 
diagnosis and fibrinogen levels were within the normal range. Considering that a decrease in 
FVII levels has been reported in hematological patients during CHT 51, we may suppose a 
reduction in FVII as a potential cause of hypocoagulability. On the other hand, the presence of 
shorter R-time could be in contrast with our hypothesis, however: - first this finding was not 
statistically significant; - second, it could mirror a concomitant endothelial cell activation and 
tissue factor up-regulation induced by CHT. 52,53 As regards the alpha-angle, it expresses the 
buildup and cross-linking of fibrin, thus needing sufficient amounts of fibrinogen, thrombin, 
and platelets. Thus, another potential mechanism responsible for TEG results may be an 
alteration of platelets-fibrinogen interactions, as suggested by a previous study in which an 
increased alpha-angle value was associated with bleeding in thrombocytopenic patients.54  
TEG results suggest that in AL, during treatment, the risk of bleeding cannot be simply 
attributed to the degree of thrombocytopenia but involves coagulant activity and interactions 
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between platelets and coagulation factors.  Comparing myelosuppression to CHT phase, we 
found that all TEG parameters significantly switched to hypocoagulation. In addition to the 
signs of hypocoagulability already seen on chemotherapy, patients showed slower clotting time 
(R-time), weaker clots (MA) and marked reduction in thrombin generation. Heubel‐moenen et 
al. found similar findings in chemotherapy induced thrombocytopenia using t-PA ROTEM. 55 
Previous studies have shown that platelets influence fibrin formation and clot structure56, 57 
suggesting that weakness of clots might be due to the low platelets count. However, even if a 
severe thrombocytopenia characterizes myelosuppression, according to the relatively 
uncommon hemorrhages in non-neoplastic severe thrombocytopenia, other mechanisms must 
be involved in determining an increased bleeding risk. A recent study suggests that the 
increased bleeding risk in thrombocytopenic cancer patients undergoing treatment could be due 
to an impaired platelets function, not counter balanced by a higher coagulation activity. 51 
Moreover,  in another study from Kim et al., patients with thrombocytopenia and severe 
bleeding had low thrombin levels.50 This is in line with our findings where a slower clot 
formation and reduced thrombin generation suggests the lack of a compensatory higher 
coagulant activity during myelosuppression. It is important to take into account that severe 
thrombocytopenia could affect TEG results. However, in the literature conflicting results on the 
relationship between R time at TEG and platelet-count are reported.55, 58 In the current study, a 
relationship between these two variables was not found. Finally, all the changes in TEG at T3 
(after CHT) revealed a hypercoagulative status when compared to the chemotherapy phase.  
These findings could mirror a restoration of the coagulation balance after a hypocoagulative 
state induced by treatment. On the other hand, the hypercoagulative status in T3 may indicate 
a residual hypercoagulable effect of CHT as previously shown in other haematological 
neoplasms 59 including acute promyelocytic leukemia (APL). 60.   
34 
 
Indeed, in patients affected by APL, treatment can convert a hypocoagulable state in a 
hypercoagulant condition. 60  Interestingly, at T3, ANC was negatively related with R and K 
and positively related to TG.  There are several aspects to consider when interpreting these 
findings: reticulated platelets are immature platelets released in the bone marrow, representing 
an early marker of thrombopoietic regeneration after chemotherapy or haemopoietic stem cell 
transplantation.61,62 Previous reports have shown immature platelets to have hyperexpressed 
haemostatic functions than mature or transfused platelets. 63, 64  In the context of these results, 
we suppose that activated immature platelets, increased after chemotherapy, may interact with 
a progressive growing ANC to induce degranualation 65 and  procoagulant mediators 
realease,thus determining a hypercoagulative state. In a previous study on thirteen 
thrombocytopenic, haemato-oncologic patients, there was no significant correlation between 
white blood cells  and R, in contrast to our results.54 A possible explanation to the contradictory 
results may be that in our study, a significant relationship between ANC and R was present 
after chemotherapy and not during it.  Concerning clinical complications, the incidence of VTE 
was 12% while hemorrhagic complications occurred in 40% of the enrolled patients. In our 
cohort, TEG parameters did not show any statistically significant difference in patients 
developing hemostatic symptoms and those who did not, at all the examined time points and 
for both type of complications.  However, this could be due to the sample size of our study. It 
should be noticed that in 80% with VTE, TEG at T0 showed decreased K and R values, while 
patients having significant bleeding showed all a more hypocoaguable profile on TEG at T0 
(longer R and K), than their non-bleeding counterparts. In addition, TEG performed the day 
before the onset of VTE symptoms, revealed signs of hypocoagulability (diminished MA, α, 
and TG) in the patient with CNS hemorrhage and in presence of PLT > 10 x 109 /L. This is in 
line with other studies, showing that TEG parameters perform better in discriminating between 
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patients having significant bleeding. Either  alone 66 or in association with platelets count 67 
than platelets count alone. Finally, in our study patients with clinical complications received an 
increased number of PLT and RBC units transfusion (p<0.05) in comparison to those without 
complications. Our findings are consistent with previous studies in which transfusions were 
associated with VTE, arterial thrombotic events (ATE) and in-hospital mortality in neoplastic 
patients. 68 A possible explanation is that anemia and severe thrombocytopenia are a surrogate 
marker of aggressive tumor biology, or for more intense cytoreductive treatments, related to 
complications. It should be noted that there was no correlation between any TEG parameter and 
conventional clotting test results in patients during all the four time-points analyzed, thus 
confirming that standard assays are not a valuable tool to monitor patients with AL. Our results 
suggest that TEG may be clinically useful to early detect changes in haemostatic status of 
patients with AL during treatment, where standard coagulation tests are known to be 
inadequate. Our findings confirm that, although AL is associated with a high risk of life-
threating bleedings, VTE occurs in a not negligible percentage of cases (12%). Prophylaxis and 
therapy of VTE is still a challenging issue in patients with AL38,39 and calls us to find tools able 
to predict thrombotic risk and drive therapeutic interventions. Additionally, TEG has shown the 
ability to detect prohemorrhagic features, besides thrombocytopenia and in presence of normal 
CCTs. Thus, TEG could contribute to guide transfusion and hemostatic therapy during the 
course and different phase of treatment in AL. Another important aspect to consider is that TEG 
is a fast and inexpensive assay with readily available results (within five to ten minutes). 
Moreover, it is an easy to handle instrumentation and ideally present in ICU and cardiology 
surgery units, thus it could be commonly available in hospitals without specialized coagulation 
centers. This study has several limitations. First, we studied patients treated with several 
chemotherapy regimens, but the number of enrolled subjects did not allow stratifying for type 
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of CHT. Second, we estimated TG levels by an algorithm of TEG and not directly by calibrated 
automated thrombogram method. Although this technique involves a time-consuming and 
complex process, which prevents its use for rapid diagnosis.69 However, to our knowledge, this 
is the first study to have systematically evaluated global hemostasis test and coagulation 
parameters in patients with AL during different phases of disease, including myelosuppression 
and after chemotherapy. 
Conclusion 
In conclusion, our findings showed the ability of TEG to reveal complex and dynamic 
abnormalities in patients with AL according to the course of the disease and its treatment. 
Further studies will clarify the role of TEG as a valuable tool to define the hemostatic profile 
of patient and individualize the approach to transfusion, bleeding management and 












10. Tables and figures 
 
Table 1. Patient Demographics and Clinical Characteristics 
N° patients 40 
Age — yr mean (range) 62 (18-80) 
Sex F/M — no. (%) 17 (43)/23(57) 
Time of follow-up –days (mean, range) 31 (7-69) 
Diagnosis — no. (%) 
 AML-NOS 
 FLT3 mutated 
 AML-NMP1 mutated 
 AML post-PV 
 AML with MDS changes 
 ALL 















 Prostatic hypertrophy 
 Hypercholesterolemia 










N° patients  29 
Treatment plan — no. (%) 
 TKI 
 Hydroxyurea 

















Abbreviation: AML: Acute Myeloid Leukemia; ALL Acute Lymphoid Leukemia; COPD: Chronic obstructive pulmonary 
disease; DM: Diabetes Mellitus; FLAG: fludarabine, cytarabine, and granulocyte colony-stimulating factor; MDS: 











Table 2. TEG parameters during all time-points of the study 
 
Test, 


















































CI, mm - 0.15+ 2.16 -0.22 + 2.2 
 
-1.95 + 3.12 
 
















TEG: thromboelastography; R:reaction time;  α (alpha-angle); K: kinetic time; MA: maximum amplitude; CI: coagulation index, TG: 



















Table 3. Laboratory and conventional coagulation tests 
 
Test, 










Hb (g/dl) 9.2 +3.1 8.4  + 0.9 8.3 +0.5 9.6 + 1.2 T0vsT1: <0.05; T1vsT2= ns; 
T1vsT3: <0.05; T2vsT3: <0.05 
Hct (%) 27.1+5.1 25.0 + 3.3 24 +1.9 28 + 4.0 T0vsT1: <0.05; T1vsT2= ns 
;T1vsT3: <0.05; T2vsT3: <0.05 
Wbc (x109/L) 31.0+48.0 5.0  + 9.1 0.79 +0.9 3.73 +  2.3 T0vsT1: <0.05;T1vsT2: <0.05; 
T1vsT3: <0.05; T2vsT3: <0.05 
Neu (x109/L) 4.4 + 10.0 1.5  + 2.9 0.11 +0.2 2.01  +  1.8 T0vsT1: <0.05; T1vsT2: <0.05; 
T1vsT3: <0.05; T2vsT3: <0.05 
Lym (x109/L) 9.6 +21.0 1.3 + 1.8 0.47 +0.3 1.24  +  1.0 T0vsT1: <0.05; T1vsT2: <0.05; 
T1vsT3: <0.05; T2vsT3: <0.05 
Mono (x109/L) 1.3 + 22.0 2.6 + 7.0 0.19 +0.6 564  + 565 T0vsT1: <0.05 ; T1vsT2:<0.05; 
T1vsT3: <0.05; T2vsT3: <0.05 
Plt (x109/L) 66+ 68 55+51 4.7 + 4.0 136 + 98 T0vsT1= ns; T1vsT2: <0.05; 
T1vsT3: <0.05; T2vsT3: <0.05 
PT-ratio 1.1  +  0.2 1.1 + 0.1 1.17 +0.3 1.12 + 0.1 T0vsT1= ns; T1vsT2=ns; 
T1vsT3=ns; T2vsT3= ns 
APTT, seconds 28 + 5 29 + 4 30 +5 31.6 + 5 T0vsT1=ns; T1vsT2=ns; 
T1vsT3=ns; T2vsT3= ns 
FBG (mg/dl)   420 + 195 335  + 199 509 +199 359 + 208 T0vsT1: ns; T1vsT2: ns; 
T1vsT3: ns; T2vsT3: ns 
DD (μg/L) 3827 + 6174    2125 +1.968 1469 +1200 984 + 1289 T0vsT1: ns; T1vsT2: ns; 
T1vsT3: <0.05; T2vsT3: <0.05 
Abbrevations: Hb: hemoglobin, WBC: white blood cell count; Neu: neutrophils; Lym: lymphocytes; Mono: monocytes; Plt: platelets; 






























A depiction of a TEG device in which a pin suspended from a torsion wire is immersed in a cup of whole blood. The 
cup is held in a heating block and continually oscillates through 4_ 450 every 5 sec. Changes in viscoelastic clot strength 
are directly transmitted to the torsion wire and detected by an electromechanical transducer. (Adapted from TEG and 
















Depiction of a TEG. Reaction time (R) is the clotting time to cause a 2-mmdisplacement during initial clot formation. Kinetics 
(K) is the clot formation time. α-Angle is the rate of clot formation. Maximum amplitude (MA) is the maximumclot strength. 
Lysis at 30 minutes (LY30) is the percent decrease in amplitude 30minutes after achieving MA. As illustrated on the right-
hand side, citrated blood is placed in a warmed cup into which a pin descends. As the cup rotates and the clot forms, the 
connection between the rotating cup and the pin induces torqueonthe pin,which is registeredby a transducer as a characteristic 





Time course of TEG-parameters in patient with acute leukemia during the course of disease and 
treatment 
a) R-time at the 4 time-points previous by the study: T0 (diagnosis), T1 (during chemotherapy), 

























b) K-time at the 4 time-points previous by the study: T0 (diagnosis), T1 (during chemotherapy), 




























c) Alpha-angle at the 4 time-points previous by the study: T0 (diagnosis), T1 (during 



























d)  Maximum-amplitude at the 4 time-points previous by the study: T0 (diagnosis), T1 (during 



























e) Thrombin generation at the 4 time-points previous by the study: T0 (diagnosis), T1 (during 



























f) Coagulation index (CI) at the 4 time-points previous by the study: T0 (diagnosis), T1 (during 
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